- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
VIDEO - Zenabis Global in Hot Water with Investors After Stumbles
The Investing News Network brings investors in the cannabis space an update on some of the biggest developments during the month of October.
October brought along the much-anticipated “Cannabis 2.0” stage of legalization in Canada; while edible products won’t be sold until December, the market celebrated the policy.
Meanwhile, Zenabis Global (TSX:ZENA) suffered through a difficult month for its share price after investors proved to be skeptical of a new rights offering to raise additional capital.
Also during the month, Hadley Ford, CEO of iAnthus Capital Holdings (CSE:IAN,OTCQX:ITHUF), told the Investing News Network (INN) that the capital-raising landscape for marijuana companies has significantly changed, with stricter guidelines.
Zenabis makes case for rights offering as stock takes hit
As mentioned, Zenabis has had a difficult month, in part due to concerns surrounding a C$20.8 million rights offering revealed toward the end of October.
Prior to the rights offering, the company was already on the downturn following the announcement of a split and delay on the expansion of its site in Langley, British Columbia.
During a conference call with investors after the rights offering news, the executive team of the company defended the offering and described it as the best option at this time for Zenabis to raise capital without affecting valuations for its shareholders.
“Zenabis determined that it was not in the best interest of shareholders to raise incremental debt from non-traditional sources, given additional debt would’ve increased cash burn until it became cash flow positive (and) increased our overall leverage, and given the requirement to raise convertible debt would’ve been meaningfully dilutive to shareholders,” CEO Andrew Grieve told investors during the call.
The company admitted it could not complete a traditional unit raising and was hard against a convertible debt offering.
iAnthus exec paints gloomy picture for cannabis investing landscape
“The actual values that exist in the (cannabis) market today bear no resemblance to what the value of the actual companies are,” iAnthus’ Ford told INN in an interview.
The executive explained that a lot of companies are struggling to raise capital as they continue operations in thriving markets, such as the US.
“We’re all getting painted with the same brush,” Ford continued. “Six months ago, anyone who smoked a joint could raise US$100 million. Now? It’s tough.”
Watch the video above to get the full details on cannabis highlights for the month of October.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.